Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV

Clinical trial NCT00527826 · COMPLETED

Trial details

NCT number: NCT00527826
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Pulmonary Disease, Chronic Obstructive

Start date: 2007-11-01
Primary completion: 2009-07-01
Enrollment: 214

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.